報價延遲最少15分鐘:2025/03/30 00:56 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.04 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-6.32/-1.80
|
|
企業價值
14.33M
|
| 資產負債 |
|
每股賬面淨值
0.45
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/03/30 00:56 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. |